Progression of chronic thromboembolic pulmonary disease without pulmonary hypertension in a case with JAK2 V617F mutation Authors: Mizuki Momoi, Atsushi Anzai, Takashi Maeda, Shogo Ikegami, Yoshiki Shinya, Takahiro Hiraide, Yasuyuki Shiraishi, Masaki Ieda Published: 2026 ABSTRACT Chronic thromboembolic pulmonary disease (CTEPD) is characterized by persistent obstruction of pulmonary arteries with organized thrombotic materials. Patients with CTEPD without pulmonary hypertension (PH) are generally considered unlikely to progress to chronic thromboembolic pulmonary hypertension (CTEPH). Here, we report a case of a 75-year-old woman with essential thrombocythemia harboring JAK2 V617F mutation, who had a history of acute pulmonary embolism. Initial evaluation of contrast-enhanced computed tomography and pulmonary angiography revealed organized thrombi predominantly in the right main and lobar pulmonary arteries, accompanied by perfusion defects on lung perfusion scintigraphy. Right heart catheterization (RHC) showed a mean pulmonary arterial pressure (mPAP) of 18 mmHg, leading to a diagnosis of CTEPD without PH. As the patient declined invasive treatment, she was followed with anticoagulation therapy alone. Three years later, her symptoms worsened, and RHC revealed an elevated mPAP of 33 mmHg, along with slight progression of thrombotic lesions and newly identified calcified deposits. She again refused invasive treatment and died one year later despite medical therapy. This case suggests that the JAK2 V617F mutation could be a risk factor for progression from CTEPD without PH to CTEPH, underscoring the importance of close follow-up and early consideration of invasive treatment in such patients.Learning objectiveThis case highlights that chronic thromboembolic pulmonary disease without pulmonary hypertension can progress to chronic thromboembolic pulmonary hypertension, particularly in patients with high-risk features such as the JAK2 V617F mutation. It underscores the importance of careful long-term follow-up and early consideration of invasive treatment despite initially normal hemodynamics. Introduction Chronic thromboembolic pulmonary disease (CTEPD) without pulmonary hypertension (PH) is defined by persistent obstruction of the pulmonary arteries with a mean pulmonary arterial pressure (mPAP) of ≤20 mmHg. While pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), and medical therapy are established treatment options for patients with chronic thromboembolic pulmonary hypertension (CTEPH), the optimal management strategy for patients with CTEPD without PH remains under debate [1]. A recent study investigating the natural history of CTEPD with no or mild PH found that neither group displayed disease progression at least up to 3 years, even symptomatic [2]. The JAK2 V617F mutation has been reported as one of the risk factors in patients with pulmonary hypertension [3], [4]. Moreover, this variant is associated with a poor treatment response in patients with CTEPH, possibly due to a prothrombotic state [3]. However, little is known about the clinical significance of this mutation in patients with CTEPD without PH. Here, we describe a patient with CTEPD without PH harboring the JAK2 V617F mutation who progressed to CTEPH three years after the initial diagnosis. The case suggests that patients with CTEPD without PH in combination with the JAK2 V617F mutation may be at increased risk of disease progression and therefore require careful and close long-term follow-up. Case report A 75-year-old woman with a history of acute pulmonary thromboembolism three years prior to presentation was referred to our hospital due to dyspnea on effort. Her symptoms had been stable for several years with apixaban 10 mg daily without interruption. She also had a history of essential thrombocythemia with the JAK2 V617F mutation, treated with 1000 mg of hydroxycarbamide. On presentation, her blood oxygen saturation was 96% on room air. A peripheral blood test showed a B-type natriuretic peptide (BNP) value of 45.5 pg/mL, platelet count of 730 × 106/μl, and hemoglobin level of 10.4 g/dL. Lung ventilation/perfusion scintigraphy revealed mismatched perfusion defects in the bilateral lower and upper lung areas, while electrocardiographic and echocardiographic changes were mild (Fig. 1A). Subsequent right heart catheterization (RHC) showed right atrial pressure (RAP) of 0 mmHg, mPAP of 18 mmHg, pulmonary vascular resistance (PVR) of 3.2 Wood units, cardiac index of 3.3 L/min/m2, and pulmonary artery wedge pressure (PAWP) of 3 mmHg. In addition, pulmonary angiography demonstrated organized clots predominantly in the right main and lobar arteries, as well as in the left segmental arteries, which were also evident on contrast-enhanced computed tomography (CT) (Fig. 2A). The typical CT findings in the lung such as mosaic perfusion patterns were not detected. Based on these findings and in accordance with current guidelines, the patient was diagnosed as having CTEPD without PH because the mPAP was below 20 mmHg [1]. Screening for prothrombotic disorders such as antiphospholipid antibody syndrome, hypothyroidism, and coagulopathy was negative, except for essential thrombocythemia. Although PEA was considered, she declined and opted for continued medical management, and apixaban 10 mg daily was continued. Although dose escalation of hydroxycarbamide was considered, the dose remained the same due to concern about anemia, and she was continued to be followed by a hematologist.Fig. 1The electrocardiogram, echocardiography, and pulmonary angiography at diagnosis (A) and three years later during disease exacerbation (B) are shown.Fig. 1Fig. 2Contrast-enhanced and non-contrast computed tomography findings at diagnosis (A) and three years later during disease exacerbation (B) are shown. Red arrows indicate organized thrombi at the central portion of right pulmonary artery. Orange arrows indicated calcified deposits within the thrombi.Fig. 2 The electrocardiogram, echocardiography, and pulmonary angiography at diagnosis (A) and three years later during disease exacerbation (B) are shown. Contrast-enhanced and non-contrast computed tomography findings at diagnosis (A) and three years later during disease exacerbation (B) are shown. Red arrows indicate organized thrombi at the central portion of right pulmonary artery. Orange arrows indicated calcified deposits within the thrombi. Having been in a stable condition for three years, she was readmitted due to worsening symptoms of dyspnea. Laboratory tests revealed a BNP level of 299.8 pg/mL, platelet count of 361 × 106/μl, hemoglobin level of 8.7 g/dL, and D-dimer level was negative. Electrocardiogram and echocardiography exhibited marked interval changes, consistent with the development to PH and right-sided heart failure (Fig. 1B). The RHC revealed her RAP of 2 mmHg, mPAP of 33 mmHg, PVR of 8.26 Wood units, and PAWP of 2 mmHg. Contrast-enhanced CT demonstrated that organized thrombi in the central portion of the right pulmonary artery were enlarged with some newly identified calcified deposits, but otherwise unaltered (Fig. 2B). These findings were confirmed by pulmonary angiography. Importantly, she had never discontinued anticoagulant treatment. She again refused invasive treatment and was managed with medical therapy, including riociguat and anticoagulant. Apixaban was switched to warfarin to allow monitoring and adjustment of anticoagulation intensity, as the thrombus had enlarged during apixaban therapy. Despite such treatment, her condition deteriorated, and she eventually died in a nursing facility one year after the follow-up RHC. Discussion CTEPD is a life-threatening disease that typically develops after acute pulmonary embolism and is classified according to the presence or absence of PH. In addition to life-long anticoagulation therapy, a multimodal treatment approach combining PEA, BPA, or pulmonary vasodilators is currently recommended for CTEPH patients. In contrast, the optimal management strategy for patients with CTEPD without PH remains controversial, with anticoagulation therapy being the standard approach. Moreover, a previous study showed that no patients with mPAP less than 21 mmHg progressed to CTEPH during a 3-year follow-up period [2], supporting the notion that CTEPD without PH generally follows a stable clinical course. However, this study was limited by small sample size and lack of genetic assessment, including JAK2 V617F mutation. Therefore, whether this conclusion applies to JAK2 V617F-positive patients remains unknown. In this case report, we demonstrate a rare case in which CTEPD without PH progressed to CTEPH three years after diagnosis in a patient harboring the JAK2 V617F mutation, despite continuous anticoagulation therapy. Imaging studies showed slight progression of proximal thrombi with calcification, without clear evidence of new embolic events. These findings suggest that progression from CTEPD without PH to CTEPH may not be attributable solely to recurrent embolism, but may also involve pulmonary vascular remodeling and increased thrombus organization. The somatic JAK2 V617F mutation, commonly associated with myeloproliferative disorders, enhances JAK-STAT signaling, leading to increased cell proliferation and inflammation [5]. In the context of pulmonary hypertension, the JAK2 V617F mutation has been shown to exacerbate PH and induce pulmonary arterial remodeling via upregulation of Acvrl1 in neutrophils in a murine model [4]. In addition, patients with the JAK2 V617F mutation are reported to be at increased risk of venous thrombosis and of new clot formation in pulmonary arteries despite ongoing anticoagulation therapy [3]. Given its proinflammatory and prothrombotic effects, it is plausible that the JAK2 V617F mutation contributed to disease progression in the present case, even at relatively normal baseline hemodynamics. Although JAK inhibitors are approved for patients with polycythemia vera and myelofibrosis, they are not approved in essential thrombocythemia due to limited evidence. In the present case, their use was not considered appropriate because of the lack of supporting evidence and the presence of anemia. However, JAK inhibition may have potential relevance in CTEPD. A meta-analysis has shown that ruxolitinib reduces venous thrombotic events in patients with polycythemia vera and myelofibrosis [6], suggesting a possible role in preventing thrombus progression. In addition, ruxolitinib has been shown to suppress inflammatory cytokine signaling via the JAK2/STAT3 pathway and to inhibit vascular smooth muscle cell proliferation in animal models [5]. These findings suggest that JAK inhibition may warrant further investigation as a potential therapeutic strategy in patients with CTEPD and JAK2 mutation. The comorbidity of essential thrombocythemia might also have contributed to disease aggravation in the patient. PH associated with myeloproliferative disorders is classified as group 5 PH [1]. As the epidemiology, hemodynamic characteristics, and prognosis of this group may differ from those of other types of PH [7], CTEPH associated with myeloproliferative disorders may represent a distinct clinical entity from classical CTEPH. Moreover, patients with essential thrombocythemia are known to be at increased risk of thrombotic events, including venous thrombosis, regardless of the presence of specific driver mutations [8]. In particular, the elevated platelet count at diagnosis may have contributed to the thrombus formation in this case. Therefore, underlying myeloproliferative disorder itself may worsen PH over time, despite adequate anticoagulant therapy. With regard to thrombus size and location, the large proximal thrombus in the right pulmonary artery was already detected at the time of diagnosis in the present case. The larger perfusion defect and central position of thrombus were reported to be risk factors for the development of CTEPH following acute pulmonary embolism [9], [10]. Given that a substantial portion of the pulmonary vascular bed was affected, it was possible that the pulmonary arterial pressure may have been particularly susceptible to elevation with additional vascular impairment, even though mPAP was initially normal. Although there have been no reports regarding progression from CTEPD without PH to CTEPH in relation to central large thrombus, close follow-up and early invasive treatment should be considered in such patients. In conclusion, this case report highlights the need for careful long-term monitoring in CTEPD without PH patients harboring the JAK2 V617F mutation. Early consideration of invasive treatment may be warranted in selected patients at high risk of disease progression, particularly those with coexisting myeloproliferative disorders. As suggested by this case, screening for the JAK2 V617F mutation may be considered in selected patients, such as those with elevated blood counts, elderly individuals with unexplained hematological abnormalities, or those with disease progression or recurrent thrombosis despite appropriate anticoagulation. Patient permission/consent statement The patient provided written informed consent for the use of clinical data for research and publication, in accordance with the study protocol approved by the local Ethics Committee (No. 20120224). Funding sources The authors have no funding sources to disclose. Declaration of competing interest The authors have no conflicts of interest to disclose.